Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor
Status:
Unknown status
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The growth and metastasis of solid tumors are dependent on angiogenesis. Endostatin, the
C-terminal proteolytic fragment of collagen XVIII, is an effective endogenous angiogenesis
inhibitor in cancer therapy in mice. Applied for clinical studies in solid tumor, however,
recombinant human endostatin protein, difficulties in a large-scale production of the
recombinant endostatin protein, and the cumbersome daily administration. Up to now, its
clinical application has been hampered by those matters. We herein constructed a adenoviral
vector ecoding human endostatin. This study will test the safety and efficacy of recombinant
human endostatin adenovirus (Ad-rhE) in the treatment of patients with advanced solid tumors.